Gustavo Viani, Associate Professor at Faculty of Medicine of Ribeirão Preto (FMRP), University of São Paulo (USP), shared on X, about a recent paper by Takamasa Mitsuyoshi et al. published in Advances in Radiation Oncology.
“Supercharged Spinal Metastases SBRT: SIB Boost Scores High Local Control
Objective
- Evaluate if GTV dose escalation via SIB-SBRT local control in spinal metastases without toxicity
Methods
- PH II, single-arm trial; 25 (28 vertebral segments)
- 30 Gy to PTV: 40–45 Gy to GTV via simultaneous integrated boost in 5 fx over 1 week
- VMAT/IMRT planning; MRI and neurologic exams at 3, 6, 12 months
Results
- 1-year LC 100%; 2-yr LC 95%
- 1-year OS 92%; 2-yr OS 72.8%
- VCF incidence: 1-yr 3.6%; 2-yr 15.6%
- No grade ≥2 myelopathy; only 1 case grade 2 pain
Clinical Relevance
- High efficacy and acceptable toxicity support larger comparative trials!”
Title: Phase 2 Trial of Stereotactic Body Radiation Therapy with Dose Escalation Using Simultaneous Integrated Boost for Spinal Metastases
Authors: Takamasa Mitsuyoshi, Peter J. K. Tokuda, Yumi Kokubo, Takahiro Iwai, Hiroyuki Inoo, Ryo Ashida, Ryosuke Nasada, Mikiko Yamashita, Hiroaki Tanabe, Shigeki Arizono, Toshiyuki Imagumbai, Masaki Kokubo
Journal: Advances in Radiation Oncology
Providing in-depth information about SBRT in this article on OncoDaily:
Success Rate and Survival After Stereotactic Radiotherapy
